Mårten Renberg1,2, Olof Jonmarker3, Naima Kilhamn4, Claire Rimes-Stigare4,5, Max Bell4,5, Daniel Hertzberg4,5. 1. Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, 171 76, Stockholm, Sweden. marten.renberg@sll.se. 2. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. marten.renberg@sll.se. 3. Department of Radiology, Karolinska University Hospital, Huddinge, Stockholm, Sweden. 4. Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, 171 76, Stockholm, Sweden. 5. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: Renal resistive index (RRI) is a promising tool for the assessment of acute kidney injury (AKI) in critically ill patients in general, but its role and association to AKI among patients with Coronavirus disease 2019 (COVID-19) is not known. OBJECTIVE: The aim of this study was to describe the pattern of RRI in relation to AKI in patients with COVID-19 treated in the intensive care unit. METHODS: In this observational cohort study, RRI was measured in COVID-19 patients in six intensive care units at two sites of a Swedish University Hospital. AKI was defined by the creatinine criteria in the Kidney Disease Improving Global Outcomes classification. We investigated the association between RRI and AKI diagnosis, different AKI stages and urine output. RESULTS: RRI was measured in 51 patients, of which 23 patients (45%) had AKI at the time of measurement. Median RRI in patients with AKI was 0.80 (IQR 0.71-0.85) compared to 0.72 (IQR 0.67-0.78) in patients without AKI (p = 0.004). Compared to patients without AKI, RRI was higher in patients with AKI stage 3 (median 0.83, IQR 0.71-0.85, p = 0.006) but not in patients with AKI stage 1 (median 0.76, IQR 0.71-0.83, p = 0.347) or AKI stage 2 (median 0.79, min/max 0.79/0.80, n = 2, p = 0.134). RRI was higher in patients with an ongoing AKI episode compared to patients who never developed AKI (median 0.72, IQR 0.69-0.78, p = 0.015) or patients who developed AKI but had recovered at the time of measurement (median 0.68, IQR 0.67-0.81, p = 0.021). Oliguric patients had higher RRI (median 0.84, IQR 0.83-0.85) compared to non-oliguric patients (median 0.74, IQR 0.69-0.81) (p = 0.009). After multivariable adjustment, RRI was independently associated with AKI (OR for 0.01 increments of RRI 1.22, 95% CI 1.07-1.41). CONCLUSIONS: Critically ill COVID-19 patients with AKI have higher RRI compared to those without AKI, and elevated RRI may have a role in identifying severe and oliguric AKI at the bedside in these patients.
BACKGROUND: Renal resistive index (RRI) is a promising tool for the assessment of acute kidney injury (AKI) in critically illpatients in general, but its role and association to AKI among patients with Coronavirus disease 2019 (COVID-19) is not known. OBJECTIVE: The aim of this study was to describe the pattern of RRI in relation to AKI in patients with COVID-19 treated in the intensive care unit. METHODS: In this observational cohort study, RRI was measured in COVID-19patients in six intensive care units at two sites of a Swedish University Hospital. AKI was defined by the creatinine criteria in the Kidney Disease Improving Global Outcomes classification. We investigated the association between RRI and AKI diagnosis, different AKI stages and urine output. RESULTS: RRI was measured in 51 patients, of which 23 patients (45%) had AKI at the time of measurement. Median RRI in patients with AKI was 0.80 (IQR 0.71-0.85) compared to 0.72 (IQR 0.67-0.78) in patients without AKI (p = 0.004). Compared to patients without AKI, RRI was higher in patients with AKI stage 3 (median 0.83, IQR 0.71-0.85, p = 0.006) but not in patients with AKI stage 1 (median 0.76, IQR 0.71-0.83, p = 0.347) or AKI stage 2 (median 0.79, min/max 0.79/0.80, n = 2, p = 0.134). RRI was higher in patients with an ongoing AKI episode compared to patients who never developed AKI (median 0.72, IQR 0.69-0.78, p = 0.015) or patients who developed AKI but had recovered at the time of measurement (median 0.68, IQR 0.67-0.81, p = 0.021). Oliguric patients had higher RRI (median 0.84, IQR 0.83-0.85) compared to non-oliguric patients (median 0.74, IQR 0.69-0.81) (p = 0.009). After multivariable adjustment, RRI was independently associated with AKI (OR for 0.01 increments of RRI 1.22, 95% CI 1.07-1.41). CONCLUSIONS:Critically illCOVID-19patients with AKI have higher RRI compared to those without AKI, and elevated RRI may have a role in identifying severe and oliguric AKI at the bedside in these patients.
Authors: Belén Ponte; Menno Pruijm; Daniel Ackermann; Philippe Vuistiner; Ute Eisenberger; Idris Guessous; Valentin Rousson; Markus G Mohaupt; Heba Alwan; Georg Ehret; Antoinette Pechere-Bertschi; Fred Paccaud; Jan A Staessen; Bruno Vogt; Michel Burnier; Pierre-Yves Martin; Murielle Bochud Journal: Hypertension Date: 2013-10-14 Impact factor: 10.190
Authors: Michael Anthonius Lim; Raymond Pranata; Ian Huang; Emir Yonas; Arto Yuwono Soeroto; Rudi Supriyadi Journal: Can J Kidney Health Dis Date: 2020-07-07
Authors: Matthew J Cummings; Matthew R Baldwin; Darryl Abrams; Samuel D Jacobson; Benjamin J Meyer; Elizabeth M Balough; Justin G Aaron; Jan Claassen; LeRoy E Rabbani; Jonathan Hastie; Beth R Hochman; John Salazar-Schicchi; Natalie H Yip; Daniel Brodie; Max R O'Donnell Journal: Lancet Date: 2020-05-19 Impact factor: 79.321
Authors: Jonathan E Millar; Reinhard Busse; John F Fraser; Christian Karagiannidis; Daniel F McAuley Journal: Lancet Respir Med Date: 2020-08-21 Impact factor: 30.700
Authors: Tomas Luther; Per Eckerbom; Robert Frithiof; Per Liss; Eleanor Cox; Miklos Lipcsey; Sara Bülow; Michael Hultström; Francisco Martinez Torrente; Jan Weis; Fredrik Palm; Susan Francis Journal: Crit Care Date: 2022-09-01 Impact factor: 19.334
Authors: Minesh Chotalia; Muzzammil Ali; Joseph E Alderman; Manish Kalla; Dhruv Parekh; Mansoor N Bangash; Jaimin M Patel Journal: Crit Care Med Date: 2021-10-01 Impact factor: 9.296